Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified β-amyloid peptides

Molecular Immunology

Volumn 46, Issue 13, 2009, Pages 2524-2532

  Rossi, Maria ^a   Piovesan, Paola ^b   Ghirardi, Orlando ^b   Mastroianni, Domenico ^a   Bombardi, Valentina ^a   Battistini, Luca ^c   Cencioni, Maria Teresa ^c   Capobianco, Debora ^a   Borsini, Franco ^b   Colombo, Maurizio ^a   Verdoliva, Antonio ^a  

^a Tecnogen SpA   (Italy)

^b Sigma Tau SpA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Amyloid peptide; Sheet conformation; Alzheimer disease; Antigen modification; Peripheral blood mononuclear cells; Simplified peptides

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN DERIVATIVE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GAMMA INTERFERON; GLYCINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BETA SHEET; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CELL LINE; CELLS, CULTURED; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 67650602079     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.05.017     Document Type: Article

References (37)

1. Benkirane N., Guichard G., Van Regenmortel H.H.V., Briand J.P., and Muller S. Cross-reactivity of antibodies to retro-inverso peptidomimetics with the parent protein histone H3 and chromatin core particle. Specificity and kinetic rate-constant measurements. J. Biol. Chem. 270 (1995) 11921-11926
2. Buckwalter M.S., Coleman B.S., Buttini M., Barbour R., Schenk D., Games D., Seubert P., and Wyss-Coray T. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J. Neurosci. 26 (2006) 11437-11441
3. Gillette Guyonnet S., Abellan Van Kan G., Andrieu S., Aquino J.P., Arbus C., Becq J.P., Berr C., Bismuth S., Chamontin B., Dantoine T., Dartigues J.F., Dubois B., Fraysse B., Hergueta T., Hanaire H., Jeandel C., Lagleyre S., Lala F., Nourhashemi F., Ousset P.J., Portet F., Ritz P., Robert P., Rolland Y., Sanz C., Soto M., Touchon J., and Vellas B. Prevention of progression to dementia in the elderly: rationale and proposal for a health promoting memory consultation (An IANA Task Force). J. Nutr. Health Aging 12 (2008) 520-529
4. Ghosh A.K., Gemma S., and Tang J. Emerging Alzheimer's disease therapies: inhibition of beta-secretase. Neurotherapeutics 5 (2008) 399-408
5. Guichard G., Benkirane N., Graff R., Muller S., and Briand J.P. Synthesis and antigenic properties of reduced peptide bond pseudopeptide analogues of a histone H3 hexapeptide. Pept. Res. 7 (1994) 308-321
6. Guichard G., Benkirane N., Zeder-Lutz G., Van Regenmortel M.H.V., Briand J.-P., and Muller S. Antigenic mimicry of natural l-peptides with retro-inverso-peptidomimetic. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9765-9769
7. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
8. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., and Nicoll J.A. Long-term effect of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
9. Jameson B.A., and Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput. Appl. Biosci. 4 (1988) 181-186
10. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
11. Legler D.F., Loetscher M., Roos R.S., Clark-Lewis I., Baggiolini M., and Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J. Exp. Med. 187 (1998) 655-660
12. Lemere C.A., Maier M., Peng Y., Jiang L., and Seabrook T.J. Novel Abeta immunogens: is shorter better?. Curr. Alzheimer Res. 4 (2007) 427-436
13. Levine H. Thioflavine T interaction with synthetic Alzheimer's disease {beta}-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993) 404-410
14. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12243-12247
15. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., and Lemere C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26 (2006) 4117-4128
16. Marino M., Ippolito A., Ruvo M., Scarallo A., Volpe S., and Fassina G. Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives. Mol. Immunol. 37 (2000) 951-960
17. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., Di Carlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
18. Morgan D., and Gitter B.D. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol. Aging 25 (2004) 605-608
19. Muller S., Guichard G., Benkirane N., Brown F., Van Regenmortel M.H.V., and Briand J.P. Enhanced immunogenicity and cross-reactivity of retro-inverso peptidomimetics of the major antigenic site of foot-and-mouth disease virus. Pept. Res. 8 (1995) 138-144
20. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
21. Pérez M., Cuadros R., Benítez M.J., and Jiménez J.S. Interaction of Alzheimer's disease amyloid beta peptide fragment 25-35 with tau protein, and with a tau peptide containing the microtubule binding domain. J. Alzheimer Dis. 6 (2004) 461-467
22. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
23. Porat Y., Abramowitz A., and Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67 (2006) 27-37
24. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., and Black R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 5 (2008) 194-196
25. Rivière C., Richard T., Vitrac X., Mérillon J.M., Valls J., and Monti J.P. New polyphenols active on beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 8 (2008) 828-831
26. Rossi M., Manfredi V., Ruvo M., Fassina G., and Verdoliva A. Sequence-simplification and chimeric assembly: new models of peptide antigen modification. Mol. Immunol. 39 (2002) 4439-4451
27. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
28. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., and Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159 (2001) 439-447
29. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., Goni F., Frangione B., and Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 24 (2004) 6277-6282
30. Solomon B. Beta-amyloid based immunotherapy as treatment of Alzheimers disease. Drugs Today (Barc.) 43 (2007) 333-342
31. Soto C., Castaño E.M., Frangione B., and Inestrosa N.C. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem. 270 (1995) 3063-3067
32. Sparey T., Clarke E., Hannam J., Harrison T., Madin A., Shearman M., and Sohal B. Sulfonamide derivatives of bridgehead substituted bicycle [4.2.1] nonanes as gamma-secretase inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 375-379
33. Strauss K.I. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav. Immun. 22 (2008) 285-298
34. Verdoliva A., Ruvo M., Cassani G., and Fassina G. Topological mimicry of cross-reacting enantiomeric peptide antigens. J. Biol. Chem. 270 (1995) 30422-30427
35. Verdoliva A., Ruvo M., Cassani G., and Fassina G. Antigenicity of topochemically related peptides. Biochem. Biophys. Acta 1253 (1995) 57-62
36. Verdoliva A., Ruvo M., Villain M., Cassani G., and Fassina G. Antigenic cross-recognition of retro and inverso peptides. In: Schneider C.H. (Ed). Peptides in Immunology (1996), Wiley, Chichester 205-211
37. Younkin S.G. Amyloid beta vaccination: reduced plaques and improved cognition. Nat. Med. 7 (2001) 18-19